# No routine measurement of gastric residual volume in paediatric critical care

Submission date 07/02/2023	<b>Recruitment status</b> Recruiting	<ul><li>[X] Prospectively registered</li><li>[X] Protocol</li></ul>	
Registration date	Overall study status	Statistical analysis plan	
05/04/2023	Ongoing	Results	
Last Edited 09/06/2025	<b>Condition category</b> Digestive System	Individual participant data	
		[X] Record updated in last year	

# Plain English summary of protocol

Background and study aims

Most children in intensive care cannot eat normally by mouth and require feeding into their stomach via a tube (a nasogastric (NG) tube or gastrostomy). It is important to provide enough calories to children through their feeds while they are critically ill, as this can help them to get off the ventilator faster, improves how quickly wounds heal and generally helps them to recover better from their illness. Ensuring children in intensive care have enough calories from feeds is a big challenge. We know from large worldwide studies that most children in intensive care get only around half of the calories they need. This is mainly due to their feeds being stopped. The most common reason is that the amount of fluid in the stomach is felt to be 'large'. Across the UK, it is a common practice in all Paediatric Intensive Care Units (PICU) for nurses to check how much food is in the stomach. A syringe is attached to the end of the feeding tube and the child's stomach contents are gently 'sucked out'. This is to see how much fluid is in the child's stomach and see how well the child is digesting their feed. This is called the gastric residual volume or GRV, often referred to as an 'aspirate'. If a child has a 'large' GRV, often feeding is stopped. However, the amount of fluid in the child's stomach is affected by many things, not just how much we feed them, but also how much gastric juice their stomach produces and some of the medicines we use slow down the stomach's actions. The measurement of this (GRV) through the NG tube or gastrostomy is known to be guite inaccurate. Therefore, a decision may be taken to stop feeds, or not to increase feeds, when there is no need to. We do not know whether it is better to measure GRV routinely or not and this is why we are doing this study. This study aims to determine the clinical and cost-effectiveness of no routine GRV measurement to guide enteral feeding and to determine if it is non-inferior to standard at least 6 hourly GRV measurements in mechanically ventilated children admitted to PICU.

## Who can participate?

Children who are mechanically ventilated and tube fed, who are aged at least 37 weeks corrected gestational age and less than 16 years

## What does the study involve?

Half of the children in the study will be assigned to the routine GRV group where their stomach contents will be measured at least every 6 hours, the common practice in most paediatric intensive care units in the UK to control for feed intolerance or the stomach getting too full. The

other half of the children will not have this done and instead will be monitored for feed intolerance/stomach fullness using clinical signs only.

What are the possible benefits and risks of participating?

While the research team cannot guarantee that taking part in this study will benefit the participants, they may receive more of their required calorie (energy) needs from their feeds, which is important for recovery and reducing the length of illness. Also, by being in this study there will be a more detailed observation of the child's calorie and feed intake, along with other things such as the time they spend on the breathing machine. If a child is selected to have their GRV measured, they will be receiving standard UK care, so there will be no difference from 'usual care'. If a child is chosen at random to 'no GRV measurement' the risk is that the child's stomach might get full, and they might vomit and inhale this vomit into their lungs. However, this risk has never been proven. There is also a risk that when GRV is aspirated and returned into the child's stomach, this may also cause vomiting. This will not take place in the no GRV group. Small studies have not found any additional risks in children who did not have their GRV measured regularly, and in some countries (France) GRV is not routinely measured.

Where is the study run from?

The study is coordinated by Intensive Care National Audit and Research Centre (ICNARC) CTU (UK)

When is the study starting and how long is it expected to run for? September 2022 to April 2026

Who is funding the study? National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact? Irene Chang (Trial Manager), irene.chang@icnarc.org

## Study website

https://www.icnarc.org/Our-Research/Studies/Current-Studies/Gastric

# **Contact information**

**Type(s)** Principal Investigator

**Contact name** Prof Lyvonne Tume

ORCID ID https://orcid.org/0000-0002-2547-8209

# **Contact details**

Edge Hill University Faculty of Health Social Care & Medicine St Helen's Road Ormskirk United Kingdom L39 4QP +44 (0)7710412142 Lyvonne.tume@edgehill.ac.uk

# Type(s)

Scientific

# Contact name

Ms Irene Chang

# **Contact details**

Trial Manager Intensive Care National Audit & Research Centre (ICNARC) Napier House 24 High Holborn London United Kingdom WC1V 6AZ +44 (0)204 513 6249 irene.chang@icnarc.org

# Type(s)

Public

**Contact name** Dr GASTRIC-PICU Team

# **Contact details**

- -United Kingdom
- gastric@icnarc.org

# Additional identifiers

EudraCT/CTIS number Nil known

**IRAS number** 322370

**ClinicalTrials.gov number** Nil known

Secondary identifying numbers CPMS 54988, IRAS 322370

# Study information

### Scientific Title

A randomised controlled trial of no routine gastric residual monitoring to guide enteral feeding in paediatric intensive care units.

### Acronym

GASTRIC-PICU

### **Study objectives**

GASTRIC-PICU study aims to identify if no routine measurement of gastric residual volume (GRV) to guide enteral feeding in paediatric intensive care units is non-inferior to the regular measurement of GRV at least 6 hourly in terms of clinical and health economics outcomes.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

Approved 15/05/2023, London-Bloomsbury REC (3rd Floor Barlow House, 4 Minshull Street, Manchester, M1 3DZ, United Kingdom; +44 (0)207104828; bloomsbury.rec@hra.nhs.uk), ref: 23 /LO/0284

**Study design** Randomized interventional study

**Primary study design** Interventional

Secondary study design Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Oral and Gastrointestinal

### Interventions

GASTRIC-PICU is a multi-centre, randomised, noninferiority, open-label trial with an internal pilot phase (with clear stop/go progression criteria to full trial) and health economic evaluation and patient follow-up at 6 months. A randomised controlled trial (RCT) design was chosen as this is the gold standard design for clinical trials.

The GASTRIC-PICU trial aims to determine the clinical and cost-effectiveness of no routine gastric residual volume (GRV) measurement to guide enteral feeding and to determine if it is

non-inferior to standard at least 6 hourly gastric residual volume measurements in mechanically ventilated children admitted to PICU. The primary clinical objective is to determine whether no routine GRV measurement is non-inferior to at least 6 hourly GRV measurements to guide enteral feeding in critically ill ventilated children in PICU in terms of a composite outcome of survival and days free from mechanical ventilation (non-inferiority) and superior in terms of achievement of their estimated energy requirement (superiority).

The primary health-economic objective is to conduct a full economic evaluation to assess the relative cost-effectiveness of these two practices. Secondary objectives are to compare the non-routine measurement with regular up to 6 hourly measurements in terms of other important patient and family-centred outcomes and costs.

We will include 4,700 patients from at least 19 paediatric critical care units. The study will use a deferred consent model due to the emergency nature of the patient population. Eligible patients will be randomised by the PICU and their parents or legal guardians will be approached for consent to continue in the study at the earliest appropriate opportunity.

Eligible patients will be randomised to one of two study arms:

1. Intervention arm - no routine GRV measurement to guide enteral feeding. Patients in this study arm will be monitored for signs of feed intolerance using clinical signs only: vomiting and other gastrointestinal or systemic signs but not by using GRV.

2. Control arm - routine (at least 6 hourly) GRV measurements to guide enteral feeding. Patients in this study arm will be monitored for feed intolerance using the GRV measurements as well as vomiting, and other gastrointestinal or systemic signs.

All other clinical care for patients in both treatment groups will be determined by the clinical team responsible for the patient's care. Data will be collected daily whilst in PICU to describe the intensity and duration of treatment, alongside routine data collection. Patients will be followed up after 6 months to ascertain their quality of life. One interim analysis will be undertaken to check for evidence of significant harm or benefit.

## **INTERNAL PILOT**

The internal pilot phase will last for ten months and will assess key progression criteria using a traffic light system. Key progression criteria will include site opening, patient recruitment, and treatment adherence. The same processes as the main RCT will be used throughout the internal pilot phase, with all patients recruited in the ten-month period included in the final analysis.

## INDEPENDENT COMMITTEES

Both a Trial Steering Committee and an independent Data Monitoring & Ethics Committee (DMEC) will be convened and will meet regularly during the trial. The DMEC will monitor recruitment and retention, protocol adherence (including adherence to treatment protocols) and patient safety (including serious adverse events) and will review the interim analysis.

### TIMELINE

Funding has been obtained from the NIHR for a 42-month period: Months 1-6: Study set-up: all approvals & preparation for the start of the trial (site sign-up and local approvals, production of materials for participating sites, conducting site initiation meetings)

Months 7-40: Recruitment/follow-up period

Months 7-16: Internal pilot stage

Month 17: First annual REC report

Month 13: First follow-up questionnaires sent

Month 18: Second DMEC and TSC meetings to review internal pilot analysis Internal pilot report

submitted to NIHR HTA Month 32: Close to recruitment Month 38: Final follow-up questionnaires Months 39-42: Analysis and dissemination Month 40: Database lock for primary analysis (clinical and economic evaluation) Commence primary analysis and write up Month 40: Lock database for longer-term outcomes Month 42: Submit primary outcome paper Collaborators' meeting Final DMEC and TSC meetings Month 42: Submit longer-term outcomes paper and draft final report to NIHR

# Intervention Type

Other

# Primary outcome measure

1. Composite outcome of survival and days free from mechanical ventilation measured using patient medical records at 30 days (non-inferiority)

2. Percentage of the child's estimated energy requirements achieved by 72 hours after randomisation (superiority) measured using patient medical records and Schofield equation at 72 hours post-randomisation

3. Incremental net monetary benefits at six months (cost-effectiveness analysis) measured using health care services questionnaire and patient medical notes at 6 months post-randomisation

# Secondary outcome measures

1. Time to the achievement of target energy requirement measured using patient medical records and Schofield equation at 72 hours post-randomisation

2. Time to the achievement of target protein requirement measured using patient medical records at 72 hours post-randomisation

3. Diagnosis of ventilator-associated pneumonia (VAP) measured using patient medical records at 30 days post-randomisation

4. Diagnosis of necrotising enterocolitis (NEC) in infants – using patient medical records at 30 days post-randomisation

5. Duration of time with no enteral feed in the first 7 days after randomisation measured using patient medical records at 7 days

6. Incidence of vomiting leading to feed stoppage in the first 7 days after randomisation measured using patient medical records at 7 days

7. Documented healthcare-acquired infections measured using patient medical records at 30 days post-randomisation

8. Length of PICU stay and hospital stay measured using patient medical records at 30 days and 6 months post-randomisation

9. Mortality at 30 days and 6 months measured using patient medical records at 30 days and 6 months post-randomisation

10. Resource use and costs measured using Health Care services questionnaires at 6 months 11. Health-related quality of life measured using the pediatric quality of life inventory (PedsQL) and the validity of the child health utility instrument (CHU9D) questionnaire data at 6 months post-randomisation

. 12. Quality-adjusted life years (QALYs) measured using PedsQL and CHU-9D questionnaire data at 6 months post-randomisation

13. Feeding measured using the feeding component of the Functional Status Score at 6 months post-randomisation

# Overall study start date

01/09/2022

Completion date 30/04/2026

# Eligibility

# Key inclusion criteria

Current participant inclusion criteria as of 20/05/2024:

1. Aged > = 37 weeks corrected gestational age and < 16 years at the time of randomisation

- 2. Enrolled within 24 hours of first meeting all the following criteria:
- 2.1. Receiving invasive mechanical ventilation (with extubation not planned in the next 48 hours)
- 2.2. Intention to start feeding or started feeding via the gastric route (including gastrostomy)

Previous participant inclusion criteria:

- 1. Aged > = 37 weeks corrected gestational age and < 16 years at the time of randomisation
- 2. Receiving invasive mechanical ventilation (with extubation not planned in the next 48 hours)
- 3. Intention to start feeding via the gastric route (including gastrostomy)

Participant type(s)

Patient

**Age group** Child

**Lower age limit** 37 Weeks

**Upper age limit** 16 Years

**Sex** Both

**Target number of participants** Planned Sample Size: 4700; UK Sample Size: 4700

# Key exclusion criteria

- 1. Post-pyloric feeding or jejunostomy
- 2. End-of-life care plan in place with limitation of resuscitation
- 3. Children on long-term mechanical ventilation

4. Current or recent gut pathology or surgery (e.g., necrotising enterocolitis (NEC), active GI bleeding, or any intestinal surgery)

5. Known to have been enrolled in the GASTRIC-PICU trial in the last 6 months

Date of first enrolment

29/06/2023

Date of final enrolment 31/10/2025

# Locations

### Countries of recruitment

England

Northern Ireland

Scotland

United Kingdom

Wales

#### **Study participating centre Cambridge University Hospitals NHS Foundation Trust** Cambridge Biomedical Campus Hills Road Cambridge United Kingdom

CB2 0QQ

### Study participating centre

University Hospitals Bristol and Weston NHS Foundation Trust Trust Headquarters Marlborough Street Bristol United Kingdom BS1 3NU

### **Study participating centre Guy's and St Thomas' NHS Foundation Trust** St Thomas' Hospital Westminster Bridge Road London United Kingdom SE1 7EH

# Study participating centre

**Great Ormond Street Hospital for Children** Great Ormond Street London United Kingdom WC1N 3JH **Study participating centre Kings College Hospital** Denmark Hill London United Kingdom SE5 9RS

**Study participating centre Leicester Royal Infirmary** Infirmary Square Leicester United Kingdom LE1 5WW

**Study participating centre Manchester University NHS Foundation Trust** Cobbett House Oxford Road Manchester United Kingdom M13 9WL

**Study participating centre Freeman Road Hospital** Freeman Road High Heaton Newcastle upon Tyne United Kingdom NE7 7DN

Study participating centre John Radcliffe Hospital Headley Way Headington Oxford United Kingdom OX3 9DU

# Study participating centre Southampton General Hospital

Tremona Road Southampton United Kingdom SO16 6YD

# Study participating centre

**St Georges Hospital** Blackshaw Road Tooting London United Kingdom SW17 0QT

### Study participating centre

**Imperial College Healthcare NHS Trust** The Bays St Marys Hospital South Wharf Road London United Kingdom W2 1BL

#### Study participating centre NHS Greater Glasgow and Clyde J B Russell House

Gartnavel Royal Hospital 1055 Great Western Road Glasgow United Kingdom G12 0XH

# Study participating centre

NHS Lothian Waverley Gate 2-4 Waterloo Place Edinburgh United Kingdom EH1 3EG

#### Study participating centre Queens Medical Centre

Derby Road Nottingham United Kingdom NG7 2UH

### **Study participating centre Leeds Teaching Hospitals NHS Trust** St. James's University Hospital Beckett Street Leeds United Kingdom

LS9 7TF

#### Study participating centre Belfast Health and Social Care Trust

Trust Headquarters A Floor - Belfast City Hospital Lisburn Road Belfast United Kingdom BT9 7AB

### **Study participating centre Birmingham Women's and Children's NHS Foundation Trust** Steelhouse Lane Birmingham United Kingdom B4 6NH

### **Study participating centre Sheffield Childrens NHS Foundation Trust** Western Bank Sheffield United Kingdom S10 2TH

### **Study participating centre NHS Staffordshire and Stoke-On-Trent Integrated Care Board** 1 Staffordshire Place

Stafford United Kingdom ST16 2LP

#### **Study participating centre Alder Hey Childrens NHS Foundation Trust** Eaton Road West Derby Liverpool United Kingdom L12 2AP

**Study participating centre The Royal Belfast Hospital for Sick Children** 274 Grosvenor Road Belfast United Kingdom BT12 6BA

**Study participating centre University Hospital of Wales** Heath Park Cardiff United Kingdom CF14 4XW

# Sponsor information

**Organisation** Intensive Care National Audit & Research Centre

### **Sponsor details**

C/o: Paul Mouncey Napier House 24 High Holborn London England United Kingdom WC1V 6AZ +44 (0)2072699277 paul.mouncey@icnarc.org **Sponsor type** Hospital/treatment centre

Website http://www.icnarc.org/

ROR https://ror.org/057b2ek35

# Funder(s)

**Funder type** Government

**Funder Name** National Institute for Health and Care Research

## Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

**Funding Body Type** Government organisation

Funding Body Subtype National government

**Location** United Kingdom

# **Results and Publications**

## Publication and dissemination plan

The results of the GASTRIC-PICU trial will be disseminated actively and extensively. This will cover both progress during the trial period and the results at the end of the study.

The outputs for the GASTRIC-PICU trial will include, but will not be limited to, the following areas:

1. Meeting and conference presentations (national and international) of study progress and results

2. Publication of study results, primary results and longer-term outcomes, including economic evaluation; and

3. Incorporation into clinical guidelines.

These separate outputs will be targeted at relevant stakeholders in formats suitable for the target audience. This will ensure that the potential benefit of GASTRIC-PICU is maximised.

Following publication, the results will also be disseminated using social media for both professionals and a lay summary that will be co-designed with the Patient Advisory Group (PAG). Dissemination will also be via UK, European and International PICU networks at meetings and special dissemination events.

### Intention to publish date

30/06/2026

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from GASTRIC@icnarc.org

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			20/09/2023	No	No
<u>Protocol file</u>	version 4.0	07/02/2025	09/06/2025	Νο	No